Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Other financing activities (2016 - 2019)

Sangamo Therapeutics (SGMO) has disclosed Other financing activities for 4 consecutive years, with $216000.0 as the latest value for Q1 2019.

  • For Q1 2019, Other financing activities fell 97.96% year-over-year to $216000.0; the TTM value through Sep 2021 reached $216000.0, down 99.16%, while the annual FY2021 figure was $943000.0, N/A changed from the prior year.
  • Other financing activities hit $216000.0 in Q1 2019 for Sangamo Therapeutics, down from $10.6 million in the prior quarter.
  • Across five years, Other financing activities topped out at $15.0 million in Q4 2017 and bottomed at -$1.0 million in Q4 2016.
  • Average Other financing activities over 4 years is $6.2 million, with a median of $5.4 million recorded in 2018.
  • Year-over-year, Other financing activities skyrocketed 1580.59% in 2017 and then plummeted 97.96% in 2019.
  • Sangamo Therapeutics' Other financing activities stood at -$1.0 million in 2016, then surged by 1580.59% to $15.0 million in 2017, then dropped by 29.57% to $10.6 million in 2018, then tumbled by 97.96% to $216000.0 in 2019.
  • According to Business Quant data, Other financing activities over the past three periods came in at $216000.0, $10.6 million, and $15.0 million for Q1 2019, Q1 2018, and Q4 2017 respectively.